May 19, 2020 / 11:56 AM / in 11 days

BRIEF-Kempharm Receives Day-74 Letter For Kp415 NDA

May 19 (Reuters) - KemPharm Inc:

* KEMPHARM RECEIVES DAY-74 LETTER FOR KP415 NDA

* KEMPHARM INC - LETTER STATED THAT NDA FOR KP415 IS SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW BY FDA

* KEMPHARM INC - DAY-74 LETTER STATED TARGET GOAL DATE UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA) IS MARCH 2, 2021

* KEMPHARM INC - DAY-74 LETTER INDICATED THAT FDA IS NOT CURRENTLY PLANNING TO HOLD AN ADVISORY COMMITTEE TO DISCUSS KP415 NDA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below